Bristol Myers Squibb - 51 Year Stock Price History | BMY

Historical daily share price chart and data for Bristol Myers Squibb since 1972 adjusted for splits. The latest closing stock price for Bristol Myers Squibb as of February 06, 2023 is 74.53.
  • The all-time high Bristol Myers Squibb stock closing price was 80.49 on December 02, 2022.
  • The Bristol Myers Squibb 52-week high stock price is 81.44, which is 9.3% above the current share price.
  • The Bristol Myers Squibb 52-week low stock price is 65.62, which is 12% below the current share price.
  • The average Bristol Myers Squibb stock price for the last 52 weeks is 73.72.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Bristol Myers Squibb Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2023 72.5663 71.6918 74.5300 71.0100 74.5300 4.41%
2022 71.4692 59.5338 80.4921 59.5338 71.3842 19.00%
2021 59.8923 57.6919 66.1344 51.5966 59.9860 2.89%
2020 55.9258 57.7134 61.4401 42.2782 58.3029 0.39%
2019 44.8478 45.8132 58.0753 38.3782 58.0753 27.86%
2018 49.9655 52.1781 59.0859 42.6063 45.4200 -12.91%
2017 48.5208 49.2530 55.6163 39.0451 52.1525 7.72%
2016 51.8571 54.5381 63.1641 40.7859 48.4162 -13.50%
2015 51.7686 47.3215 57.2195 46.0799 55.9701 19.24%
2014 40.8318 40.4281 48.4430 36.2864 46.9398 14.18%
2013 33.3319 24.5372 41.3623 24.5372 41.1087 69.95%
2012 24.3426 24.9753 26.5615 22.8673 24.1884 -3.78%
2011 20.3250 18.0984 25.1751 17.2175 25.1394 39.43%
2010 17.1596 16.8301 18.7979 14.9116 18.0304 8.74%
2009 13.8073 14.8373 16.8364 10.8795 16.5806 14.78%
2008 12.9764 15.3294 15.8867 10.5807 14.4459 -6.05%
2007 16.4753 14.8684 18.4603 14.7106 15.3758 4.75%
2006 13.2277 12.3784 14.6788 11.1610 14.6788 19.92%
2005 12.6791 12.9464 13.7827 11.2013 12.2400 -6.16%
2004 12.5828 14.4351 15.0695 11.3219 13.0431 -7.27%
2003 12.1051 11.3164 14.0662 9.9507 14.0662 29.02%
2002 14.1195 22.9419 23.1450 9.4476 10.9020 -52.36%
2001 25.5332 31.4812 31.4812 21.9862 22.8836 -29.71%
2000 25.4584 27.9085 32.5555 18.9179 32.5555 17.10%
1999 29.3677 27.8754 33.7553 24.7200 27.8003 -2.80%
1998 23.1054 20.0115 28.6022 18.9923 28.6022 42.93%
1997 15.9541 11.1046 20.5996 11.1046 20.0115 77.07%
1996 9.3676 8.5270 11.9184 8.0812 11.3016 32.15%
1995 6.7623 5.6878 8.5768 5.6040 8.5519 53.26%
1994 5.2205 5.2575 5.7712 4.6945 5.5799 6.10%
1993 5.1813 5.7756 5.7756 4.5591 5.2593 -9.48%
1992 6.0859 7.3695 7.4113 5.2972 5.8100 -21.16%
1991 6.5026 5.3954 7.3695 4.9702 7.3695 35.84%
1990 4.6815 4.4336 5.4372 3.9842 5.4253 24.55%
1989 3.7702 3.3150 4.4020 3.2866 4.3558 28.87%
1988 3.1477 3.1953 3.3984 2.8443 3.3800 9.90%
1987 3.5236 3.1166 4.0633 2.6966 3.0756 0.78%
1986 2.7959 2.4288 3.2459 2.2304 3.0519 24.71%
1985 2.1649 1.8931 2.4978 1.8377 2.4472 26.48%
1984 1.7136 1.5932 1.9393 1.5422 1.9349 23.98%
1983 1.4343 1.2375 1.7594 1.1636 1.5607 25.65%
1982 1.0977 0.9743 1.3529 0.9444 1.2421 26.58%
1981 0.9668 0.9420 1.0805 0.8520 0.9813 5.46%
1980 0.7520 0.6719 0.9490 0.5679 0.9305 36.16%
1979 0.6382 0.6579 0.7065 0.5772 0.6834 3.50%
1978 0.6220 0.6165 0.7342 0.5218 0.6603 6.31%
1977 0.6016 0.6280 0.6579 0.5333 0.6211 -2.00%
1976 0.6752 0.6395 0.7642 0.5714 0.6338 -0.35%
1975 0.5735 0.4721 0.6799 0.4351 0.6360 37.39%
1974 0.4290 0.4317 0.5184 0.2920 0.4629 8.10%
1973 0.5647 0.6326 0.6592 0.4063 0.4282 -32.80%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $158.293B $46.159B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00